Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

295
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
295
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

292
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
292
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

293
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
293
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

318
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
318
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

303
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
303
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

423
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Hidradenitis Suppurativa on Sexual Function: A Multicentered Cross-Sectional Study.

International journal of dermatology·2026
Same author

Predicting late-onset psoriasis from lifestyle-associated serum metabolites: Opportunities and caveats.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Recommendations for the diagnostic work-up of cutaneous small vessel vasculitis - Position Statement of the European Academy of Dermatology and Venereology Vasculitis and Vasculopathy Task Force.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Shared Inflammatory Mechanisms in Psoriasis and Periodontitis: A Cross-Sectional Study.

Oral diseases·2025
Same author

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Related Experiment Video

Updated: Nov 17, 2025

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

15.4K

Experimental Therapeutic Solutions for Behcet's Disease.

Burçin Cansu Bozca1, Erkan Alpsoy1

  • 1Akdeniz University School of Medicine, Department of Dermatology and Venereology, Antalya, Turkey.

Journal of Experimental Pharmacology
|February 19, 2021
PubMed
Summary

Behcet's disease (BD) is a chronic vasculitis often starting with mucocutaneous lesions. Early diagnosis and new targeted therapies, including biologics, improve outcomes and reduce mortality in this complex inflammatory condition.

Keywords:
Behcet’s syndromealgorithmsetiologymorbiditymortalitytherapeutics

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Related Experiment Videos

Last Updated: Nov 17, 2025

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

15.4K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.5K

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Behcet's disease (BD) is a chronic systemic vasculitis characterized by recurrent inflammation affecting multiple organs.
  • Mucocutaneous lesions, such as oral and genital ulcers, are common early symptoms crucial for timely diagnosis and management.
  • Genetic factors, particularly HLA-B*51, and environmental triggers like microbial agents and microbiome alterations are implicated in BD pathogenesis.

Purpose of the Study:

  • To review the current understanding of Behcet's disease etiopathogenesis, focusing on genetic and immunological mechanisms.
  • To highlight the importance of early recognition of mucocutaneous lesions for disease management and prevention of major organ involvement.
  • To discuss recent advancements in treatment strategies for Behcet's disease, including novel targeted therapies.

Main Methods:

  • Review of recent genome-wide association studies (GWAS) identifying genetic predisposing factors like HLA-B*51.
  • Analysis of immunological pathways involving antigen-presenting cells (APCs), T-cell responses (Th1, Th17, Treg), and cytokine signaling.
  • Evaluation of clinical data on the efficacy and safety of existing and emerging therapeutic agents.

Main Results:

  • HLA-B*51 is the most significant genetic risk factor for Behcet's disease.
  • Interactions between HLA-B*51 and ERAP1 influence T-cell responses, contributing to disease development.
  • Newer treatments, including apremilast and biologics (anti-TNF-α, IL-1, IL-6, IL-17, IL-12/23 antagonists), show high efficacy in managing mucocutaneous and organ-specific manifestations.

Conclusions:

  • Early diagnosis of Behcet's disease based on mucocutaneous lesions is critical for preventing severe organ damage.
  • Understanding the immunopathogenesis has led to the development of targeted therapies that significantly improve patient outcomes and quality of life.
  • Biologics and targeted small molecules offer effective treatment options for patients with severe or refractory Behcet's disease, reducing mortality rates.